国科恒泰 reported revenue of ¥3.16B for the period ended 2026-06-30, -14.0% year on year. Net income was ¥0.01B, a 0.2% net margin on a 9.3% gross margin. The largest revenue line is 血管介入治疗类材料 at 79% of the total. Free cash flow for the period was ¥0.19B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥3.16B | -14.0% |
| Gross profit | ¥0.29B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | -87.7% |
| Gross margin | 9.3% | Net margin 0.2% |
| Revenue Q/Q | +1.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| 血管介入治疗类材料 | ¥2.51B | 79.4% |
| 其他产品 | ¥0.22B | 6.9% |
| 非血管介入治疗类材料 | ¥0.20B | 6.4% |
| 骨科材料 | ¥0.20B | 6.2% |
| 其他(补充) | ¥0.02B | 0.7% |
| 神经外科材料 | ¥0.01B | 0.3% |
| 口腔材料 | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥2.87B | 90.7% |
| R&D | ¥0.01B | 0.2% |
| SG&A | ¥0.24B | 7.5% |
| Tax & other | ¥0.01B | 0.2% |
| Item | Amount |
|---|---|
| Total assets | ¥6.26B |
| Total liabilities | ¥3.76B |
| Shareholders' equity | ¥2.50B |
| Equity / assets | 39.9% |
| Operating cash flow | ¥0.20B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥0.19B |
| Cash conversion (OCF / net income) | 4469% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
敷尔佳 ・ 科净源 ・ 凌玮科技 ・ 致欧科技 ・ 鼎泰高科 ・ 通达海 ・ 天山电子 ・ 挖金客 ・ 赛维时代 ・ 蜂助手 ・ 天键股份 ・ 未来电器
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies